Tisium receives €4.2m to expand bulk syringe capacity

Tisium, a specialist in developing programmable biomorphic polymers for tissue reconstruction, has secured €4.2 million of non-diluting funding from BPFrance as part of the France 2030 plan to expand its production capacity for large volume syringes.

Tisium is developing a portfolio of products that leverage its family of biosynthetic, biomorphic and programmable polymers, which are the foundation of the company’s technology platform. Currently, the company has a pipeline of seven products in three areas, including atraumatic sutureless nerve repair, hernia repair and cardiovascular sealants. Each product is designed to enhance the tissue rebuilding process. The company develops supplement delivery and activation tools for improved performance and utility of its products.

Christophe Bancel, CEO of Tisium, said: “This new funding reflects the confidence of the French State in the strength of our project and the potential of our solutions. This will allow us to rapidly scale up our production capacity, but also help us enrich our platform. Thus we will be able to meet the demand of surgeons and allow a large number of patients to benefit from our products once they are approved by the regulatory authorities. This will also contribute to re-industrialisation and employment growth in France.

Tisium technology is based on research and intellectual property from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women’s Hospital), who co-founded the company in 2013.